Loading
A phase 3 trial of Ivosidenib in biliary tract cancer, run by Servier Affaires Médicales, active and no longer recruiting.
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma is a phase 3 interventional study registered as NCT05876754 by Servier Affaires Médicales, with 299 participants enrolled, started 2023-05-03 and due to reach its primary completion in 2027-12-01. Interventions recorded: Ivosidenib Oral Tablet.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/